Investor relations
BioRegenis is developing a portfolio of proprietary programmes and is considering investors to support the next phases of development.
- BRG-BCS · TRL level
- TRL 3
- 28%
- BRG-PV · TRL level
- TRL 6
- 61%
- BRG-CG · TRL level
- TRL 9
- 95%
- BRG-PTLB · TRL level
- TRL 5
- 50%
- BRG-BMG · TRL level
- TRL 2
- 17%
- BRG-ROB · TRL level
- TRL 2
- 15%
Average maturity
44%
No payment takes place on this site.
The portfolio
The company is considering investors to support the next phases of development.
The programmes cover biosensors, drug safety software, computational biotechnology and products for personal health.
The programmes sit at very different stages of maturity, from TRL 2 to a product already on the market, and the portfolio is built so that the progress of one does not depend on the outcome of another.
We publish the state of progress precisely for that reason: anyone assessing an investment should be able to do it on current data, not on a presentation built to convince.
Estimated stake
This page is for information purposes only. It does not constitute a public offering of financial products, a solicitation to invest, or financial advice. Requests received are assessed individually: there is no automatic subscription process, and any transaction is reserved for selected parties and is concluded solely on the basis of the specific contractual documentation.
What the raise funds
The resources are earmarked for the technical and regulatory milestones that de-risk the portfolio.
BioChip Skin. A working biosensor prototype integrated with the microfluidic module, and component validation.
BioRegenis PV. Completion of validation and start of use in an operational environment.
CareGamers. Consolidation of the distribution network and first documented commercial results.
Intellectual property. Extension and continuation of the patent procedures under way.
Documentation available. On request and once a confidentiality agreement is signed, we make available in a reserved area: the institutional presentation and development plan, technical documentation and intellectual property status, financial statements and shareholding structure, the structure of the transaction, and a demo of the BioRegenis PV software.
The risks
An investment in an early-stage company carries risks that must be considered before any assessment of return.
Programmes can stop. A negative outcome in a research stage, in validation or in patent examination can end a programme for good.
The horizon is long. Development is measured in years. Invested capital is not liquid and no secondary market is available to resell it on.
The stake can be diluted. Later funding rounds can reduce the percentage held by existing investors.
The regulatory path is not guaranteed. Authorisations and patent grants depend on independent authorities and on requirements that can change.
The loss can be total. In the event of failure, invested capital may not be recovered in whole or in part.
Anyone assessing an investment should seek independent advice.
How it works
- 01You give your details and the amount you are considering.
- 02The BioRegenis team receives the expression of interest and assesses it individually.
- 03We contact you to continue and, once a confidentiality agreement is signed, open access to the documentation.
Register your interest
Fill in the form and the team will get back to you. No commitment, no payment.